Securities code: Honz Pharmaceutical Co.Ltd(300086) securities abbreviation: Honz Pharmaceutical Co.Ltd(300086) Announcement No.: 2022023
Honz Pharmaceutical Co.Ltd(300086)
Announcement on matters related to applying for comprehensive credit line from financial institutions
The board of directors has not recorded, omitted or guaranteed the truthfulness, completeness or material misrepresentation of the company’s announcement.
Honz Pharmaceutical Co.Ltd(300086) (hereinafter referred to as “the company”) held the 23rd Meeting of the 5th board of directors and the 18th meeting of the 5th board of supervisors on April 6, 2022, deliberated and adopted the proposal on applying for comprehensive credit line from financial institutions, which needs to be submitted to the 2021 annual general meeting of shareholders for deliberation. The details are hereby announced as follows:
1、 Overview of the situation
In order to meet the needs of the company’s production, operation and project investment funds, the company and its wholly-owned subsidiaries, holding subsidiaries and holding subsidiaries intend to apply for a comprehensive credit line of no more than RMB 1.5 billion from relevant financial institutions, and provide joint and several liability guarantee of no more than RMB 1.5 billion for the loans within the comprehensive credit line of financial institutions.
The above comprehensive credit is mainly used for long-term and short-term loans, working capital loans, mortgages, bank acceptances, trade financing, letter of guarantee, opening letters of credit, pledge of bills, bill pledge loans and other financial unit credit businesses of the company and its wholly-owned subsidiaries, holding subsidiaries and holding subsidiaries for daily production and operation, project investment and construction and M & A investment. The specific credit line shall be subject to the specific contract signed between the company and banks and other relevant financial institutions. Within the credit term, the credit line can be recycled. For the specific business under the comprehensive credit of the above financial institutions, the company and its wholly-owned subsidiaries, holding subsidiaries and holding subsidiaries can provide mutual guarantees. The guarantee amount shall not exceed 1.5 billion yuan, and the guarantee methods are joint and several liability guarantee, mortgage guarantee and pledge guarantee.
In order to improve efficiency, the company proposes to authorize Mr. Hong Jiangyou, chairman of the board of directors, to fully handle the specific matters related to the company and its wholly-owned subsidiaries, holding subsidiaries and holding subsidiaries applying for credit or providing guarantee to financial institutions according to the actual business needs of the company, and to represent the company and its wholly-owned subsidiaries, holding subsidiaries The holding subsidiary company shall sign all contracts, agreements, vouchers and other legal documents related to all credit (including but not limited to credit, loan, guarantee, mortgage, financing, etc.) within the above comprehensive credit line. The legal responsibilities and obligations of the documents related to the above credit financing business signed by the chairman Mr. Hong Jiangyou in accordance with the resolution formed by this proposal shall be borne by the company.
The authorization period of the above authorization limit is from the date of deliberation and approval of the 2021 annual general meeting of shareholders to the date of holding the 2022 annual general meeting of shareholders. The credit or guarantee beyond the above comprehensive credit line and guarantee scope shall be resubmitted to the board of directors or the general meeting of shareholders for deliberation in accordance with the relevant provisions of the articles of association.
2、 Basic information of the guaranteed
(I) Guangdong Kangda Pharmaceutical Marketing Co., Ltd. (hereinafter referred to as “Kangda marketing”)
1. Basic information of Kangda marketing: Kangda marketing was established on December 4, 2002, with a registered capital of 9 million yuan and a legal representative of Hong Jiangtao. Its registered place is units 2609, 2610, 2611 and 2612, No. 69, Xianlie Middle Road, Yuexiu District, Guangzhou, Guangdong Province. Business scope: Sales of class I medical devices; Sales of class II medical devices; Wholesale of cosmetics; Cosmetics retail; Wholesale of daily necessities; Sales of daily necessities; Sales of maternal and infant supplies; Sales of personal hygiene products; Sales of sanitary supplies and disposable medical supplies; Sales of chemical products (excluding licensed chemical products); Food detergent sales; Sales of disinfectants (excluding hazardous chemicals); Sales of special equipment for oil refining and chemical production; Instrument sales; Sales of special packaging equipment; Sales of special pharmaceutical equipment; Information consulting services (excluding licensed information consulting services); Health consulting services (excluding diagnosis and treatment services); Marketing planning; Non residential real estate leasing; Wholesale of drugs; Drug retail; Class III medical device business; Food business; Sales of health food; Sales of infant formula milk powder; Technology import and export; Import and export of goods.
2. Relationship with the company: Kangda marketing is a wholly-owned subsidiary of the company.
3. The financial data of Kangda marketing is shown in the following table:
Unit: Yuan
December 31, 2021 December 31, 2020
Total assets 2305622826922728320806
Net assets 1088019694111322924105
Total liabilities 1217603132811405396701
Including: total bank loans 0
Total current liabilities 1217603132811405396701
Asset liability ratio 52.81% 50.18%
Operating income 4074276063836589768283
Total profit -581718937166750758
Net profit -44272716414209277
(II) Guangdong Kangda Pharmaceutical Co., Ltd. (hereinafter referred to as “Kangda pharmaceutical”)
1. Basic information of Kangda pharmaceutical: Kangda pharmaceutical was established on June 16, 2014, with a registered capital of RMB 70 million, the legal representative is Wang Yong, and the registration place is No. 6, Yangfan street, Cuiheng new area, Zhongshan City. Business scope: drug production; Pharmaceutical trading; R & D and technology promotion services of drugs and biological products; Food production; Food circulation; Class II and III medical device manufacturers; Class II and III medical device business enterprises; Production and sales: class I medical devices; R & D and development: general electronic equipment, medical electronic equipment, medical inspection equipment, hospital automation equipment, medical consumables and related products; China trade; Import and export of goods and technologies (except those prohibited by laws and administrative regulations, and projects restricted by laws and administrative regulations can be operated only after obtaining permission); (for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments.
）(for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments)
2. Relationship with the company: Kangda pharmaceutical is a wholly-owned subsidiary of the company.
3. The financial data of Kangda pharmaceutical is shown in the table below:
Unit: Yuan
December 31, 2021 December 31, 2020
Total assets 2898889647431448172146
Net assets 209910168821449061794
Total liabilities 79977947869999110352
Including: total bank loans 40510596384684349415
Total current liabilities 38071373143948315879
Asset liability ratio 27.59% 31.80%
Operating income 0
Total profit -457960106 -259823834
Net profit -457960106 -195019895
(III) Hainan Kangzhi Biotechnology Co., Ltd. (hereinafter referred to as “Kangzhi technology”)
1. Basic information of Kangzhi Technology: it was established on November 13, 2003, with a registered capital of RMB 33.25 million and a legal representative of Teng Yingjun. Its registered address is room 23a08, building 13, rongchuang Meilun Xiyu phase I, plot e-01, Hainan Ecological Software Park, Laocheng Town, Chengmai County, Hainan Province. Business scope: licensed items: Sales of disinfectants (excluding hazardous chemicals); Wholesale of drugs; Food business; Sales of health food; Sales of infant formula milk powder; Class III medical device business; Import and export of goods (for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments) general projects: technological research and development of biochemical products; Sales of class I medical devices; Sales of class II medical devices; Wholesale of cosmetics; Cosmetics retail; Sales of personal hygiene products; Sales of sanitary supplies and disposable medical supplies; Sales of daily necessities; Wholesale of daily necessities; Sales of daily necessities; Wholesale of kitchenware, sanitary ware and daily sundries; Medical research and experimental development; Information consulting services (excluding licensed information consulting services); Retail of medical masks; Wholesale of medical masks; Daily mask (non-medical) sales; Retail of protective articles for medical staff; Wholesale of protective articles for medical staff; Sales of labor protection articles; Category II medical device retail (except for the licensed business, it can independently operate the projects that are not prohibited or restricted by laws and regulations) (the general business projects can be operated independently, and the licensed business projects can be operated with relevant licenses or approval documents) (the business activities of the projects that must be approved according to law can be carried out only with the approval of relevant departments.)
2. Relationship with the company: Kangzhi technology is a wholly-owned subsidiary of the company.
3. The financial data of Kangzhi technology is shown in the following table:
Unit: Yuan
December 31, 2021 December 31, 2020
Total assets 1465486304811881806354
Net assets 621333492562553232
Total liabilities 84415281235626453122
Including: total bank loans 50000000 0
Total current liabilities 84415281235626453122
Asset liability ratio 57.60% 47.35%
Operating income 103654782368056344855
Total profit -49722216370311487
Net profit -42018307250549470
(IV) Beijing Shunxin Xiangyun Pharmaceutical Co., Ltd. (hereinafter referred to as “Xiangyun pharmaceutical”)
1. Basic information of Xiangyun pharmaceutical industry: it was established on January 1, 1981 with a registered capital of 152.25 million yuan. Its legal representative is Hongjiang you. Its registered place is Linhe Industrial Development Zone, Shunyi District, Beijing. Business scope: manufacturing chemicals, Chinese patent medicines, nourishing and nutritional drugs, pharmaceutical plastic packaging boxes and containers.
2. Relationship with the company: the company holds 51% equity of Xiangyun pharmaceutical, which is the holding subsidiary of the company. 3. The financial data of Xiangyun pharmaceutical is shown in the following table:
Unit: Yuan
